Compare iShares Semiconductor ETF (SOXX) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Semiconductor ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares Semiconductor ETF trades at $509.94 (market cap $44.53B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: iShares Semiconductor ETF is far larger — about 5.9× Spyre Therapeutics Inc. Common Stock's market cap, and iShares Semiconductor ETF is more actively traded (8,354,155 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold iShares Semiconductor ETF for 47 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SOXX | SYRE | |
|---|---|---|
Market Cap | $44.53B | $7.52B |
Volume | 8,354,155 | 1,441,031 |
Sector | Sector/Thematic | Health |
52-Week High | $655.01 | $108.92 |
52-Week Low | $268.10 | $22.18 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXX trades at $543.9, down 0.17% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The semiconductor ETF faces mixed sentiment with strong AI-driven earnings growth projections but elevated valuation concerns. Recent news highlights Michael Burry's expanded short position while other analysts point to continued earnings momentum supporting the sector.
The semiconductor sector outlook remains bifurcated between strong AI-driven fundamentals and valuation risks. SOXX's investment case hinges on sustained AI infrastructure demand, though current technical weakness and high multiples relative to broader markets warrant caution. Key risks include sector concentration and potential AI development slowdowns.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
